The microbiome field has grown significantly - 4D has delivered consistent progress year-on-year to build a leading position

  • Founded on over two decades of research, the Company was formed in 2014 and listed on the UK stock market.
  • From the outset, we constructed a library of bacteria isolated from healthy human samples, which now stands at more than 6,000 strains.
  • We have built a drug discovery platform, known as MicroRx, which has shown the ability to rapidly identify bacteria from our library that have therapeutically relevant effects.
  • Starting in late 2014, the Company has initiated 17 live biotherapeutic programmes across a broad range of diseases.
  • The Company has received FDA Orphan Designation for its programmes in paediatric Crohn’s disease and paediatric Ulcerative Colitis.
  • We have developed humanised preclinical models, which since 2015 have allowed us to test our products in more disease-relevant settings and improve their translational potential.
  • The Company commenced a clinical study of Blautix in patients with IBS in 2015. This trial has now been completed and successfully reached its primary objective.
  • In November 2015, 4D announced that it had developed a live biotherapeutic which shows efficacy in preclinical models of cancer.
  • In 2016, we established a proprietary microbiome profiling platform, MicroDx, to analyse the microbiome and aid the diagnosis and treatment of patients.
  • In August 2016, we commenced dosing in patients of our live biotherapeutic for paediatric Crohn’s disease.
  • In 2017, we completed the first phase of our MicroDx clinical development programme, demonstrating significant differences between the microbiome of IBS patients and healthy individuals, independent of traditional IBS sub-types
  • The same year also saw GMP certification granted for the company's ~1,500 m² development and manufacturing facility.
  • In 2018, we are targeting four clinical programmes by year end, including two immuno-oncology studies in the UK and US.